AARD

Aardvark Therapeutics Inc

Add to Watchlist

Advanced Chart

9.370

-0.06(-0.636%)1D

Line

Candle

YTD

High

9.600

Open

9.430

VWAP

9.23

Vol

254.18K

Mkt Cap

204.02M

Low

8.820

Amount

2.35M

EV/EBITDA(TTM)

Total Shares

21.77M

77.67M

EV/OCF(TTM)

P/S(TTM)

Aardvark Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. The Company targets biological pathways associated with alleviating hunger that has the potential to deliver transformative outcomes for patients. It is focused on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its initial compounds target TAS2Rs expressed in the gut lumen, which normally respond to the nutrients in food and participate in the gut-brain axis. Its wholly owned lead product candidate, ARD-101 (denatonium acetate monohydrate), is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which it has initiated a Phase III clinical trial for hyperphagia associated with Prader-Willi Syndrome (PWS).

8 Analyst Rating

Wall Street analysts forecast AARD stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for AARD is 30.75 USD with a low forecast of 19.00 USD and a high forecast of 50.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

8 Buy

0 Hold

0 Sell

Strong Buy

Current: 9.370

Low

19.00

Averages

30.75

High

50.00

Current: 9.370

Low

19.00

Averages

30.75

High

50.00

BTIG

initiated

$26

2025-11-07

Reason

BTIG

Price Target

$26

2025-11-07

initiated

Reason

BTIG initiated coverage of Aardvark Therapeutics with a Buy rating and $26 price target. Aardvark is a clinical stage biopharmaceutical company developing ARD-101, a TAS2R agonist for Prader Willi syndrome, and ARD-201 for weight loss and weight rebound prevention, the analyst tells investors in a research note. The firm believes ARD-101's "excellent" safety profile and "differentiated" mechanism are underappreciated by the Street. The real share upside, however, comes from ARD-201 and the opportunity to prevent weight regain from GLP-1 discontinuations, contends BTIG.

JonesResearch

NULL -> Buy

initiated

$33

2025-10-01

Reason

JonesResearch

Price Target

$33

2025-10-01

initiated

NULL -> Buy

Reason

JonesResearch initiated coverage of Aardvark Therapeutics with a Buy rating and $33 price target. Aardvark is a clinical-stage biotech company focused on treating obesity and hyperphagia, the analyst tells investors in a research note. The firm says the company is "gearing up for a transformative year" with two major datasets in the second half of 2026.

Stifel

initiated

$24

2025-09-29

Reason

Stifel

Price Target

$24

2025-09-29

initiated

Reason

Stifel initiated coverage of Aardvark Therapeutics with a Buy rating and $24 price target. The firm believes the company's ARD-101 is an "under-the-radar," late-stage Prader-Willi syndrome play. Stifel believes the drug has a higher probability of sucess than the shares currently imply, creating a "compelling setup." At a $200M enterprise value, Aardvark's risk/reward is "heavily upside-biased," the analyst tells investors in a research note.

RBC Capital

Outperform

maintain

$20 -> $19

2025-08-14

Reason

RBC Capital

Price Target

$20 -> $19

2025-08-14

maintain

Outperform

Reason

RBC Capital lowered the firm's price target on Aardvark Therapeutics to $19 from $20 and keeps an Outperform rating on the shares after its Q2 results. The quarter contained a few timeline slippages as the go-forward clinical plans take clearer shape, most notably the highly-anticipated Prader-Willi phase 3 for '101 now expected in Q3 of 2026 vs. early-2026 previously, though incorporation of pediatric patients in that study may help increase potential effect size and probability of success, the analyst tells investors in a research note.

H.C. Wainwright

Buy

initiated

$40

2025-06-30

Reason

H.C. Wainwright

Price Target

$40

2025-06-30

initiated

Buy

Reason

H.C. Wainwright initiated coverage of Aardvark Therapeutics with a Buy rating and $40 price target. The emerging biopharmaceutical company is developing a novel, gut-restricted approach to achieving satiety in patients with obesity and hyperphagic conditions, notes the analyst. Aardvark's lead candidate, ARD-101, is a proprietary formulation of denatonium acetate and the safety profile of ARD-101 in Prader-Willi patients appeared innocuous, with no adverse events worse than Grade 1, the analyst noted.

See All Ratings

Valuation Metrics

The current forward P/E ratio for Aardvark Therapeutics Inc (AARD.O) is -2.71, compared to its 5-year average forward P/E of -3.82. For a more detailed relative valuation and DCF analysis to assess Aardvark Therapeutics Inc 's fair value, click here.

Forward PE
Forward EV/EBITDA
Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-3.82

Current PE

-2.71

Overvalued PE

-1.75

Undervalued PE

-5.89

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-2.85

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

-0.20

Undervalued EV/EBITDA

-5.50

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

104.24

Current PS

0.00

Overvalued PS

337.07

Undervalued PS

-128.58